Late-onset biopsy-proven lupus nephritis without other associated autoimmune diseases: severity and long-term outcome

Imagem de Miniatura
Arquivos
art_UGOLINI-LOPES_Lateonset_biopsyproven_lupus_nephritis_without_other_associated_autoimmune_2019.PDF (87.96 KB)
Citações na Scopus
11
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SAGE PUBLICATIONS LTD
Autores
STAGNARO, C.
MOSCA, M.
Autor de Grupo de pesquisa
Citação
LUPUS, v.28, n.1, p.123-128, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background/Purpose Lupus nephritis (LN) usually develops within the first years of systemic lupus erythematosus (SLE) onset and rarely after that. There are scarce studies comparing early- versus late-onset nephritis (before versus after five years of SLE diagnosis). The aim of this study was to compare the severity and long-term outcome (after 7 years) in these two, late-onset and early-onset, nephritis groups. Methods This study included 93 patients from rheumatology tertiary centers from Brazil and Italy, all of them with biopsy-proven LN with > 7 years follow-up. Patients were divided in two groups: early-onset nephritis (n = 75) and late-onset nephritis (n = 18). Clinical and laboratorial data were obtained using a standardized electronic chart database protocol carried out at 1-6 months interval and established in 2000. Patients >50 years or with concomitant autoimmune diseases were excluded. Variables evaluated at the LN presentation were Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), creatinine, albumin, anti-DNA positivity and nephritis class. Variables evaluated at the long-term outcome (after 7 years) were Systemic Lupus International Collaborating Clinics Damage Index (SDI), creatinine, dialysis and mortality. Results The average time of LN presentation was 10.94 +/- 3.73 years for the late-onset and 1.20 +/- 1.60 years for the early-onset group. Their similar nephritis duration (12.44 +/- 3.2 versus 13.28 +/- 4.03 years, p = 0.41) and comparable mean ages (49.17 +/- 9.9 versus 44.11 +/- 10.8 years old, p = 0.06) allow a more accurate comparison. Regarding severity, late-onset was similar to early-onset group: SLEDAI (8 (range: 6-22) versus 12 (range: 2-24), p = 0.47), creatinine (1.36 +/- 0.94 versus 1.36 +/- 1.13 mg/dl, p = 0.99); albumin (2.84 +/- 0.65 versus 2.59 +/- 0.84 mg/dl, p = 0.30); proteinuria (3.77 +/- 2.18 versus 5.01 +/- 4.51 g/vol, p = 0.26); proliferative nephritis (44% (n = 8) versus 60% (n = 45), p = 0.23). There was also no difference in the long-term outcomes between groups: SDI (1 (range: 0-5) versus 0.5 (range: 0-5), p = 0.27); creatinine (2.04 +/- 2.38 versus 1.69 +/- 2.26 mg/dl, p = 0.56); dialysis (22% (n = 4) versus 13% (n = 10), p = 0.46) and mortality (0% (n = 0) versus 12% (n = 9), p = 0.19). Conclusion This study provides novel evidence of comparable long-term outcomes between late-onset and early-onset nephritis, which is most likely explained by the observation that at presentation, the clinical, laboratorial and histological features of late-onset and early-onset nephritis are similar. This suggests that there should be no distinct treatment targets and therapeutic interventions for the late- and early-onset groups.
Palavras-chave
Lupus nephritis, outcomes, systemic lupus erythematosus, early-onset nephritis, late-onset nephritis
URI
https://observatorio.fm.usp.br/handle/OPI/30787
Referências
  1. Aljohani R, 2017, LUPUS, V26, P1190, DOI 10.1177/0961203317696593
  2. ALJohani R, 2016, ARTHRITIS RHEUMATOL
  3. Bertsias G, 2008, LUPUS, V17, P437, DOI 10.1177/0961203308090031
  4. Boddaert J, 2004, MEDICINE, V83, P348, DOI 10.1097/01.md.0000147737.57861.7c
  5. Dall'Era M, 2015, ARTHRITIS RHEUMATOL, V67, P1305, DOI 10.1002/art.39026
  6. Erkan D, 2014, ARTHRITIS RHEUMATOL, V66, pS1
  7. Faurschou M, 2006, J RHEUMATOL, V33, P1563
  8. Fiehn C, 2003, ANN RHEUM DIS, V62, P435, DOI 10.1136/ard.62.5.435
  9. Francois H, 2016, NAT REV NEPHROL, V12, P82, DOI 10.1038/nrneph.2015.174
  10. Gladman D, 1996, ARTHRITIS RHEUM, V39, P363, DOI 10.1002/art.1780390303
  11. Gladman DD, 1999, ARTHRITIS RHEUM-US, V42, P1785
  12. Goules A, 2000, MEDICINE, V79, P241, DOI 10.1097/00005792-200007000-00005
  13. Hahn BH, 2012, ARTHRIT CARE RES, V64, P797, DOI 10.1002/acr.21664
  14. HELIN HJ, 1995, ARTHRITIS RHEUM, V38, P242, DOI 10.1002/art.1780380213
  15. Hochberg M. C., 2015, RHEUMATOLOGY
  16. Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928
  17. Hui M, 2013, LUPUS, V22, P328, DOI 10.1177/0961203312474084
  18. Jaryal A, 2017, INDIAN J MED RES, V145, P166, DOI 10.4103/ijmr.IJMR_163_16
  19. Mok CC, 2013, ARTHRITIS RHEUM-US, V65, P2154, DOI 10.1002/art.38006
  20. Mok CC, 1999, AM J KIDNEY DIS, V34, P315, DOI 10.1016/S0272-6386(99)70361-6
  21. Moon SJ, 2011, J RHEUMATOL, V38, P2588, DOI 10.3899/jrheum.110363
  22. NOSSENT HC, 1990, ARTHRITIS RHEUM, V33, P970, DOI 10.1002/art.1780330708
  23. Parikh SV, 2015, SEMIN NEPHROL, V35, P465, DOI 10.1016/j.semnephrol.2015.08.008
  24. Parikh SV, 2014, CLIN J AM SOC NEPHRO, V9, P279, DOI 10.2215/CJN.05040513
  25. POLLAK VE, 1964, J LAB CLIN MED, V63, P537
  26. Rabbani MA, 2010, LUPUS, V19, P1573, DOI 10.1177/0961203310375704
  27. Rovin BH, 2014, RHEUM DIS CLIN N AM, V40, P537, DOI 10.1016/j.rdc.2014.04.004
  28. Schieppati A, 2009, EVIDENCE BASED NEPHR, P244
  29. Seligman VA, 2002, AM J MED, V112, P726, DOI 10.1016/S0002-9343(02)01118-X
  30. Sinico RA, 2010, CLIN J AM SOC NEPHRO, V5, P1211, DOI 10.2215/CJN.00460110
  31. Takahashi Y, 2009, MOD RHEUMATOL, V19, P293, DOI 10.1007/s10165-009-0154-4
  32. Tomic-Lucic A, 2013, CLIN RHEUMATOL, V32, P1053, DOI 10.1007/s10067-013-2238-y
  33. Varela DC, 2008, ANN RHEUM DIS, V67, P1044, DOI 10.1136/ard.2008.088740
  34. Yu F, 2017, NAT REV NEPHROL, V13, P483, DOI 10.1038/nrneph.2017.85

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/17